AFT Pharmaceuticals Ltd (ASX: AFP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AFT Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$420.55 million
P/E Ratio
35.13
Dividend Yield
0.33%
Shares Outstanding
104.87 million
Earnings per share
0.140
Dividend per share
0.01
Year To Date Return
37.12%
Earnings Yield
2.85%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AFT Pharmaceuticals Ltd (ASX: AFP)
Latest News
Broker Notes
This ASX small-cap drug company could more than triple in value: Broker
Dividend Investing
15 ASX shares going ex-dividend before EOFY
Healthcare Shares
This ASX healthcare company's profit has rocketed 24%
Healthcare Shares
75% upside: Broker tips two ASX healthcare shares
Healthcare Shares
What's with the AFT Pharmaceuticals (ASX:AFP) share price today?
Healthcare Shares
Why the AFT Pharmaceuticals (ASX:AFP) share price is in focus
ASX Share Market News
Why the AFP Pharmaceuticals (ASX:AFP) share price is marching higher
Coronavirus News
Coronavirus: ASX pharmacy networks report surge in demand
Coronavirus News
Are ASX pharmaceutical shares a bargain buy right now?
Share Gainers
Why the AFT Pharmaceuticals share price is up 55% since April
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 19 Jun 2024 | $0.0098 | 0.00% | Final | 04 Jul 2024 |
| 16 Jun 2023 | $0.0069 | 0.00% | Final | 04 Jul 2023 |
AFP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About AFT Pharmaceuticals Ltd
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. Its feature brands include Crystaderm, Maxigesic, Coco-Scalp, Maxiclear, Eyecare Hub, and Allergy Hub. It operates through the following geographical segments: Australia, New Zealand, Southeast Asia, and Rest of the World. The Australia segment caters to the Australian market. The New Zealand segment focuses in the head office function, supplier relationships and procurement of stock, and regulatory, marketing, and finance activities of the group. The Southeast Asia segment relates in the sales activities in Brunei, Hong Kong, Malaysia, Philippines, Singapore and Vietnam markets. The Rest of the World segment comprises of out licensing of internet protocol developments to markets in which the firm does not have a presence and the export of products to export markets. The company was founded by Hartley and Marree Atkinson on September 4, 1997 and is headquartered in Auckland, New Zealand.
AFP Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | $4.10 | $0.10 | 2.50% | 3,552 | $4.11 | $4.13 | $4.09 |
| 30 Jul 2026 | $4.00 | $0.05 | 1.27% | 963 | $3.97 | $4.00 | $3.97 |
| 29 Jul 2026 | $3.95 | $0.35 | 9.72% | 9,105 | $3.90 | $3.95 | $3.90 |
| 28 Jul 2026 | $3.60 | $0.03 | 0.84% | 1,972 | $3.55 | $3.60 | $3.55 |
| 27 Jul 2026 | $3.57 | $-0.18 | -4.80% | 18,878 | $3.74 | $3.74 | $3.50 |
| 24 Jul 2026 | $3.75 | $0.46 | 13.98% | 13,245 | $3.42 | $3.75 | $3.42 |
| 17 Jul 2026 | $3.29 | $0.10 | 3.13% | 6,025 | $3.29 | $3.29 | $3.29 |
| 13 Jul 2026 | $3.19 | $0.06 | 1.92% | 30 | $3.22 | $3.22 | $3.19 |
| 10 Jul 2026 | $3.13 | $-0.17 | -5.15% | 7,020 | $3.18 | $3.21 | $3.12 |
| 09 Jul 2026 | $3.30 | $0.16 | 5.10% | 102 | $3.30 | $3.30 | $3.30 |
| 07 Jul 2026 | $3.14 | $0.10 | 3.29% | 7,453 | $3.04 | $3.14 | $3.04 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Andrew Michael Lane | Non-Executive Director | Sep 2023 |
Mr Lane has more than 30 years of experience of leadership in the global pharmaceuticals industry with expertise across a range of disciplines including finance, manufacturing, sales, marketing, and strategy. Most recently he was Global President of Abbott Laboratories Pharma Division where he led a multi-billion-dollar operation that had 30 manufacturing plants, 12 Innovation and Development sites and 40,000 staff covering more than 100 countries. Before that he was Vice President of Takeda, Asia Pacific, where he managed the company's operations in 12 countries, which included three factories and 2,000 staff. He has also held senior roles with multi-national pharmaceutical companies Nycomed, DKSH, Novartis, and Sandoz. He is Chair of the Risk Committee.
|
| Mr David Mark Flacks | Non-Executive ChairmanNon-Executive Director | Jun 2015 |
Mr Flacks is a former Chair and former Director of the Suncorp New Zealand group of companies and is the Chair of Todd Corporation and several environmentally focused pro bono organizations. He is a former chair of the NZ Markets Disciplinary Tribunal and the NZX Regulatory Governance Committee and a former member of the Takeovers Panel. He is a director of boutique corporate law firm Flacks & Wong. David was for many years a Senior Corporate Partner at Bell Gully and was General Counsel and Company Secretary of Carter Holt Harvey during the 1990's. He is a member of the Risk Committee.
|
| Ms Marree Atkinson | Chief of Staff Co-founderManaging Director | Sep 2012 |
Ms Atkinson previously practiced at Waikato Hospital.
|
| Mr Hartley Atkinson | FounderChief Executive OfficerExecutive Director | Sep 1997 |
Dr Atkinson worked at Swiss multinational pharmaceutical company, Roche, for eight years where he held positions as Sales & Marketing Director, Medical Director, Product Manager and Medical Manager. Prior to his work at Roche, Hartley was a Drug Information Pharmacist and Researcher at the Department of Clinical Pharmacology, Christchurch Hospital. Hartley is the author of several scientific publications, and his work has been published in the New England Journal of Medicine.
|
| Dr Ted Witek | Non-Executive Director | Jan 2021 |
Dr Witek served Boehringer Ingelheim Pharmaceuticals for nearly 25 years in clinical research and leadership roles, including CEO of its Canadian and Portuguese operations. Ted was also Chief Scientific Officer & Senior Vice President, Corporate Partnerships, at Innoviva and on the Board of Directors of Canada's Research-Based Pharmaceutical Companies. He is currently Professor & Senior Fellow at the University of Toronto's School of Public Health & Leslie Dan Faculty of Pharmacy.
|
| Ms Allison Yorston | Non-Executive Director | Nov 2024 |
Ms Yorston has more than 20 years of blue-chip fast-moving consumer goods, telecommunications and retail marketing experience obtained across Australia and New Zealand at senior management and C-suite levels. She is currently Director of Marketing at Griffins Snacks and is a former Director of the Australian Beverages Council and a former Chief Marketing Officer at Suntory Beverage & Food Oceania. Prior to Suntory she held senior marketing roles at Vodafone, Fonterra and Sanitarium. She is a member of the Risk Committee.
|
| Mr Malcolm Tubby | Chief Financial OfficerCompany Secretary |
-
|
|
| Malcolm Tubby | Chief Financial OfficerCompany Secretary |
-
|
|
| Ioana Stanescu | Chief Scientific Officer |
-
|
|
| Louise Clayton | Director International Business |
-
|
|
| Scott Crawford | General Manager Promoted Products |
-
|
|
| Murray Keith | Group Marketing Manager |
-
|
|
| Vladimir Ilievski | Regulatory Affairs Manager |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hartley Atkinson & Colin Mckay | 72,259,496 | 68.91% |
| Accident Compensation Corporation NZCSD | 7,397,399 | 7.05% |
| Forsyth Barr Custodians Limited | 5,366,681 | 5.12% |
| HSBC Nominees A/C Nz Superannuation Fund Nominees Limited NZCSD | 1,687,342 | 1.61% |
| BNP Paribas Nominees (NZ) Limited NZCSD | 1,035,696 | 0.99% |
| BNP Paribas Nominees (NZ) Limited NZCSD i | 1,009,539 | 0.96% |
| New Zealand Depository Nominee Limited | 916,622 | 0.87% |
| Queen Street Nominees Ltd No.6 NZCSD | 901,087 | 0.86% |
| Hama Holdings Limited | 867,826 | 0.83% |
| Forsyth Barr Custodians Limited i | 845,129 | 0.81% |
| Queen Street Nominees Ltd No.2 NZCSD | 414,254 | 0.40% |
| Garrett Smythe Limited | 390,912 | 0.37% |
| Custodial Services Limited | 332,205 | 0.32% |
| FNZ Custodians Limited | 328,622 | 0.31% |
| JP Morgan Nominees Australia Limited | 300,000 | 0.29% |
| HSBC Nominees (New Zealand) Limited NZCSD | 223,644 | 0.21% |
| Joeri Yvonne Jozef Sels | 212,832 | 0.20% |
| Queen Street Nominees Ltd No.4 NZCSD | 202,699 | 0.19% |
| Jbwere (Nz) Nominees Limited | 201,040 | 0.19% |
| David Mark Flacks & Adina Rita Betty Halpern | 158,764 | 0.15% |
